|
CN111467317A
|
|
Pharmaceutical composition containing atorvastatin calcium and preparation method thereof
|
|
CN111514110A
|
|
Pharmaceutical composition containing escitalopram oxalate and preparation method thereof
|
|
CN111514111A
|
|
Pharmaceutical composition containing mosapride citrate and preparation method thereof
|
|
CN111362856A
|
|
Method for producing atorvastatin calcium by using micro-reaction device
|
|
CN111450073A
|
|
Pharmaceutical composition containing cinacalcet hydrochloride and preparation method thereof
|
|
CN111419855A
|
|
Pharmaceutical composition containing celecoxib and preparation method thereof
|
|
CN111484453A
|
|
Synthesis method of celecoxib
|
|
CN111349052A
|
|
Synthesis method of mosapride citrate
|
|
CN111533662A
|
|
Synthesis method of citalopram intermediate
|
|
CN112154140A
|
|
Compound and application thereof in synthesizing bulk drug of Brivaracetam (Brivaracetam)
|
|
CN111018734A
|
|
Synthesis method of cinacalcet hydrochloride intermediate
|
|
CN110357790A
|
|
Compound and its purposes in synthesis Bu Waxitan bulk pharmaceutical chemicals
|
|
CA3103332A1
|
|
Compound and use thereof in synthesis of brivaracetam intermediate and crude drug
|
|
CN111601790A
|
|
Heteroaryl compounds as protein kinase inhibitors
|
|
CN105473595A
|
|
Carboxylic acid compounds in treatment of diabetes mellitus
|
|
CN105451741A
|
|
Inhibitors of bruton's tyrosine kinase
|
|
CN104230892A
|
|
Compounds for improving kinase activity and application thereof
|
